Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Email was sent to Stephanie Diaz concerning the Net Operating Losses and also why the going concern was not removed this just completed quarter with all that cash on hand.
Her reply" "NOL's are still available for use and going concern will be reevaluated at year end 10K in July"
Maybe Janet Bleecker change her name to Laura E. Benjamin???
Maybe this is what SK has been doing - hot off the press
*NOT THE SHARPEST TOOL IN THE SHED!
In Modesto, CA, Steven Richard King was arrested for trying to hold up a Bank of America branch without a weapon. King used a thumb and a finger to simulate a gun. Unfortunately, he failed to keep his hand in his pocket. (hellooooooo...!!!)
Constructs binding to phosphatidylserine and their use in disease treatment
Abstract
Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are methods of using the new construct compositions, therapeutic conjugates and combinations thereof in tumor vasculature targeting, cancer diagnosis and treatment, and for treating viral infections and other diseases.
Inventors: Thorpe; Philip E. (Dallas, TX), Luster; Troy A. (Dallas, TX), King; Steven W. (Ladera Ranch, CA)
Assignee: Board of Regents, The University of Texas System (Austin, TX)
Peregrine Pharmaceuticals, Inc. (Tustin, CA)
Family ID: 36693034
Appl. No.: 11/339,392
Filed: January 24, 2006
ABOVE FROM THE PATENT ITSELF
Disclosed are surprising new methods and compositions for isolating extracellular microvesicles such as exosomes, particularly disease-related and phosphatidylserine (PS)-positive extracellular microvesicles as exemplified by tumor- and viral-derived exosomes. The methods of the invention are rapid, efficient, cost-effective and, importantly, are suitable for use with large volumes of biological fluids and produce antigenically intact extracellular microvesicles and exosomes. The methods and compositions are based on the surprising use of acetate buffers to isolate large quantities of extracellular microvesicles, particularly tumor-derived exosomes, from solution, without damaging their morphological or functional properties or antigenicity.
I would love to have Free the Mice back to comment on the value of the IP.
It is NEVER a profit/loss . . . until you sell.
Dr. Robert L. Garnick, also known as Rob, Ph.D., serves as Senior Vice President of Regulatory Affairs at Stemcentrx, Inc. Dr. Garnick served as Head of Regulatory Affairs at Peregrine Pharmaceuticals Inc., since October 19, 2009 until December 1, 2017.
https://www.bloomberg.com/research/stocks/people/person.asp?personId=234121&privcapId=189510
Interesting read . . .
Months After Approval, Breakthrough Cancer Drug Given to Just Five Patients
By Michelle Cortez , Caroline Chen , and Natasha Rausch
December 14, 2017, 4:00 AM CST Updated on December 14, 2017, 8:47 AM CST
- Delays in getting novel therapy put sales estimates at risk
- No Medicare coverage, one-by-one rulings by private insurers
Photographer: David Paul Morris/Bloomberg
Two months after Gilead Sciences Inc.’s breakthrough treatment was approved in the U.S. to treat a deadly form of blood cancer, only a tiny handful of patients have actually gotten the costly therapy, while others linger on waiting lists.
Five people have received the treatment, called Yescarta, at the 15 cancer hospitals authorized to administer it in the U.S., the hospitals told Bloomberg. Waiting lists for the $373,000 treatment have grown to at least 200 people, shrinking only as some very sick patients have died.
Doctors at the cancer centers blame holdups in getting the treatment paid for by Medicare and Medicaid, the two giant U.S. government health programs, as well as some of the U.S.’s largest insurers.
“The biggest issue has been insurance, particularly with Medicare and Medicaid,” said Michael Bishop, director of the cellular therapy program at the University of Chicago Medicine, one of the advanced hospitals that were cleared to administer the complicated treatment. “There’s no billing codes for this. It’s been difficult, to be very blunt.”
Those payment delays -- which may not be resolved for months -- have forced the hospitals to choose between putting millions of dollars at risk, or asking dying patients to keep waiting despite the availability of a potential cure.
Estimates at Risk
The delays also mean Gilead is likely to miss Wall Street’s estimates of early sales for Yescarta. Analysts have predicted the therapy will bring in $9.4 million in 2017, implying about 20 more patients would need to be treated in the next two weeks. Based on reports by the medical centers doing the billing procedures, that figure seems unrealistically high.
Gilead is “confident that Yescarta will be covered by payers,” spokeswoman Sonia Choi said in an email. The drugmaker expects about a third of patients to be on Medicare and will continue to “engage actively with Medicare to ensure we are doing all we can to support access.”
Gilead shares declined 1.8 percent to $75.20 at 9:44 a.m. in New York on Thursday. The stock had gained 6.9 percent this year through Wednesday, trailing the Nasdaq Biotechnology Index, which rose 21 percent.
Representatives for the Centers for Medicare and Medicaid Services, the federal agency that oversees the programs, didn’t immediately respond to requests for comment.
Yescarta is part of a new class of cancer therapies called CAR-T that involve a complicated process of extracting immune-system cells from a patient, modifying them in Gilead’s manufacturing plants to make them capable of attacking tumors, and re-infusing them into the person.
Yescarta and Novartis AG’s Kymriah were only approved in the last several months. Because CAR-Ts are so new -- and because the one-time, bespoke therapies involve a blend of hospital care, boutique biological manufacturing and supplemental drugs to guide patients through the treatments -- insurers and government plans have found themselves in uncharted territory.
The clock is ticking for Gilead. The company currently has the market to itself for hard-to-treat lymphoma, a deadly cancer of the blood. As it gets the infrastructure in place to treat patients and get paid, it’s rivals are drawing closer. Novartis has filed for U.S. Food and Drug Administration approval of Kymriah for that form of blood cancer, and Juno Therapeutics Inc. plans to follow next year.
Read More: Cancer Immunotherapy Offers New Promise but Peril Too
Private insurance companies are making coverage decisions for Yescarta on a case-by-case basis, while the Medicare program for the elderly hasn’t created a reimbursement code for the treatment -- meaning hospitals don’t have any guarantee they’ll be paid.
Medicare coverage is critical for the 10,000 people with the form of relapsed non-Hodgkin lymphoma the therapy was approved to treat, since more than half of patients are already over age 65 -- when the program’s eligibility starts -- at the time they’re first diagnosed, according to the National Cancer Institute.
Anthem Inc. said it will cover the procedure. None of the other big insurers provided information about coverage in response to questions from Bloomberg. Choi, the Gilead spokeswoman, said the “vast majority” of commercial payers have confirmed coverage.
Never Seen Before
The 15 centers that responded to Bloomberg included MD Anderson Cancer Center in Houston; Stanford University in California; and Mayo Clinic in Rochester, Minnesota. On top of the five patients who got treated, about a dozen additional patients who have started a weeks-long process to get Yescarta, that begins with having their immune-system cells collected and sent to Gilead.
Insurance hurdles often emerge for novel therapies, especially if they’re as complex and costly as Yescarta. Yet Sattva Neelapu, a professor of lymphoma and director of translational research at MD Anderson, said he’s never seen anything like this.
“We have to work out a spot agreement for each patient,” Neelapu said. “Once we do enough patients there is a template in place, and it’s easier for future patients.”
The total cost per Yescarta patient, when including hospital and doctors fees, will be well in excess of $575,000 and could reach $1 million, doctors said. Since hospitals have to buy the treatment at full cost from Gilead, most places are waiting to have insurer guarantees of reimbursement before moving ahead.
Waiting List of 100
MD Anderson, which has more than 100 patients on a waiting list, has started treatment for a few, after getting them to sign waivers that they will be responsible for the costs if insurance doesn’t pay. Bishop, of the University of Chicago Medicine, said he doesn’t want to turn down any patients, but the prospect of losing $1 million per patient is unsustainable. The hospital has 10 people on its waiting list.
Stanford has decided to take patients regardless of insurance provider.
“My institution is bearing that risk because it’s the right thing to do,” said David Miklos, an associate professor of medicine at the university. “But it’s a huge risk and it’s keeping me awake at night.”
The new therapy is an essential part of the drugmaker’s big bet on the oncology market. Gilead, based in Foster City, California, spent $11.9 billion two months ago to buy Yescarta’s maker, Kite Pharma Inc., in its biggest-ever deal.
— With assistance by Zachary Tracer
https://www.bloomberg.com/news/articles/2017-12-14/cancer-patients-with-little-time-left-wait-for-gilead-s-new-drug
Agree . . WOW, only one question. I am going back into my self-imposed hibernation - see you guys in a year again. Still holding my shares, I will continue to lurk on the board. Too much Rhetoric!
music . . . sucks! like sitting at the dentist waiting for the pain and agony to start!
Wish I knew how you did that, but thanks
I also have a Fidelity account.
And I can confirm this is EXACTLY who Ralphazard see's. This is presently showing on my PPHM news on my account as of this date and time of this message.
There are also no other links or etc to go anyplace.
I also tried to take a screen shot of it and it will not copy onto this message.
Well, I missed my projection and feel chagrined by missing it so badly. I am happy they kept to the 10/12 yearly projection, I am beginning to think this will be wishful thinking. What type of "excuse" will they use for over projecting - especially since they are on record indicating this is NOT including the big three.
I have not listened to the conference call - I hope to find hope in something they said, but - quite frankly - I am deeply dismayed at these results. Good thing I have a long time before retirement. I think I will inadvertently drop my crystal ball!
Quote:
I was correct with my 1.4 projection last quarter. Will I be correct this quarter with my projection of 2.1M? We shall see in a few days! By the way - keep in mind the projected annual is between 10-12 Million. I think we will be much closer to the 10 than the 12.
Still rubbing the ol' crystal ball trying to get a clearer picture.
All IMO, of course. - E
ARGH!!!!!!!!!!!
- E
I was correct with my 1.4 projection last quarter. Will I be correct this quarter with my projection of 2.1M? We shall see in a few days! By the way - keep in mind the projected annual is between 10-12 Million. I think we will be much closer to the 10 than the 12.
Still rubbing the ol' crystal ball trying to get a clearer picture.
All IMO, of course. - E
It was webcast last year audio only. I remember Rob gibing the details on how the process works in obtaining approval and the preparation it takes for a BLA submittion (500,000 pages already). I also remember how it abruptly ended and everyone jumped on the conspiracy wagon once the question and answer portion began.
September 9, 2015 conference call. I hope we have some more information. I am on the fence waiting until the last possible to vote my shares.
YOU, MY FRIEND, ROCK! THANKS SO MUCH! -E
Is anyone aware of free private messaging on Friday's with Ihub, I believe it is between 4 and 5 EST -seems to me I have heard that before, but can not confirm if true. Can anyone confirm. Thanks in advance.
-e
Correct, an there in lies the hockey stick aspect to sales. They will take off, I truly believe that, but not "just yet" IMO. We shall see. I would be stoked with 2.1 Million, I just do not see it happening.
1.4 million is what my crystal ball says, despite my continuously rubbing trying to get a clearer picture. I suspect next quarter will be much bigger, about 50% higher, or to about 2.1 million for the quarter.
Edmund Fitzgerald's demise came in November. Maybe the second look-in will coincide with that, but I expect remaining afloat instead of sinking to the bottom of Lake Superior.
LLLLLOOOOOOOOONNNNNNNNNGGGGGGGGGG on PPHM!
I can't recall. Is it normal for CYRX to post earnings just prior to the opening.
SHHHHHH . . . IT'S THE QUIET PERIOD DURING THE ROAD SHOW . . .
The cult like board you speak of has an exceptionally well balanced intro section that allows people to start their own DD, then make their own accurate and informed decision concerning the stock. They can continue to study the stock through others opinions, and also learn who knows their stuff and who has an agenda. They can choose on their own whom to follow or not follow. However, there is banter back and forth, and it is WELCOMED, it is healthy for a balanced vetting of a company. Most of what is written is not work repeating, but if you look deep enough, and long enough into one's posts, you can certainly figure out if there is an agenda, and also what that agenda is, and include that in your own DD. If you feel the "person" is credible, you just may end up learning something.
And there is the beauty of a message board - learning something, but you have to take the good with the bad. I just detest losing good people due to a personal attach. I have seen a lot of them "disappear" on the other board - and losing them hurts the board, and in turn everyone else.
laser777 - we are speaking the same language here. I/O will not increase shipments for the next several quarters, but this will ultimately add value in the long run. Right now, this company is in need execution NOW!
I am on the record indicating my opinion is that they can and will do it, hence why I am still holding my shares.
I would like to commend you on your post. It is well written with valid points, and most supported with links for other broad members to decide if they wish to go down those paths to enhance their DD or not.
Your post is without hostility, well reasoned, logical, and not only enhances your credibility by supplying sources for your points, but provides additional food for thought to help in ones own DD. All in all, your post helps the board.
Thank You.
In the interest of full disclosure, I am a moderator on another board that is one of the most read in all of IHUB. I am not the reason it is one of the most read, but I do know what needs to be on a board and not on a board. There is no place for personal attacks, and had I been the moderator of this board, most of you would not have seen the CRAP that just spewed forth as I would have deleted it. ALL opinions, long and short have a place on a board, but there must be facts to back your position.
The other board is in the I/O (short for immune-oncology) board and there are great things in store for cancer coming up (dare I say cures), but there is not as great a need for Cryogenic shipping in the clinical trials as some on this board may think as the numbers of patients is small.
I have requested to become a moderator of this board. If successful (based on Ihub's approval) I hope some of the BS can end so that posting don't need to deleted.
The ball is in their court.
The PR campaign that has consisted of approximately the last several weeks showcases the progress that has been accomplished. These supporting companies need to translate into actual sales and this will be evidenced through increase sales that I expect will continue in excess of 20% in the quarterly conference calls, and more importantly, the SEC Filings.
The Board of Directors: The current board of directors is the best it is has every been. I totally supported the departure of CJ, and in fact, purchased additional shares at that time. This is empirical data that has compromised just some of the DD is keeping this stock in my portfolio.
It grieves me to see the infighting on this board. I read everything on this board and research everything I can on CYRX. I like what I see recently, but agree a reverse split generally does not help. I have researched this on my own, and come to my own conclusion through my own DD. I have chosen to stay with the company in the only way possible - and that is by not selling.
Epic Krak, - simply Epic
-E
Very Profound and True Volgoat! Your statement that is: "Only way PPHM moves is with institutions and they aren't buying based on tweets and articles and a tv show.....lol"
This is nice information, but understand this is under the caveot that this is a forward looking statement. Thus, we can not hold CYRX to this statement coming true. I truly believe they are going to underpromise and over deliver, as this is what I would be doing if I were running the show.
I would like to see them remove the "going concern clause" with that much cash on hand. This is something concrete we can grasp on, but this could also open up the II. With a going concern, some II may not be able to purchase shares, even if they wanted to based on their protocols.
I am long, and have been for quite some time, but my first foray into Cryoport was at $7.40/sh a long time ago, and I have dollar cost averaged down to below $0.90/sh until the reverse split a few days ago. I am angry, frustrated, beaten and bruised, and but so very thankful that some of the previous board members have decided to move on. Based on these developments, and some of the latest, I am still in!
I too have all my chips pushed into the middle of the table. We just need to keep the faith!
-E
EPCJMC - 12/31/15 = $2.6309 -- 6/30/16 = $8.5938
I would like to give special mention to using the 4 decimal places in honor of any rampant manipulation, that may or may not be going on, since I can not confirm or deny such action has been done in the past, is presently being done, or may be started in the future.
I am just saying! Or not saying! Of course, all IMO
Thank you Cheynew - your a true blessing! -E
Anyone know the next date supposed progress of the CSM law suite? I do not have searching capability. Thanks in advance.
You just keep on doing what your doing, your aces with me
-e
HEY MD - KEEP THE FAITH! - Here is what I hope adds a little inspiration to your doing the right thing, see any parallels???
-E
(Bloomberg) -- Lumber Liquidators Holdings Inc.’s stock plunge over the past week, fueled by allegations of excessive formaldehyde in its flooring, can be traced back to a blog post from an obscure 25-year-old short seller.
Xuhua Zhou, who had dropped out of UCLA’s doctoral program in finance and become an individual investor, took an interest in Lumber Liquidators about two years ago. After seeing a surge in the company’s gross profit margin, Zhou learned that it sourced some products from China. That raised his suspicions that safety might have been skirted in pursuit of lower costs, he said in an interview.
Zhou, who was born and raised in China, already had experience researching suppliers in the country, so he began investigating. His digging ultimately led to lawsuits, a “60 Minutes” report and accolades from the well-known short seller Whitney Tilson, who also bet against Lumber Liquidators.
? © Provided by Bloomberg
“It’s pretty amazing what he did on his own,” said Tilson, head of Kase Capital Management, calling Zhou “the pioneer” of the Lumber Liquidators story.
Lumber Liquidators, a retailer of hardwood flooring and accessories, is now under fire for allegedly selling products with more formaldehyde than is allowed by California law. The “60 Minutes” piece, which relied in part on undercover reporters and hidden cameras, showed managers at three Chinese factories admitting to using false labeling that made it look like the products met regulations. In a response to the allegations, Lumber Liquidators said that “60 Minutes” used flawed testing in its reporting and that its floors are safe.
Stock Tumble
The “60 Minutes” piece contributed to a more than 40 percent stock decline in the past week. While Lumber Liquidators rebounded 5 percent to $40.78 on Tuesday, it remains down 39 percent this year.
When Zhou began looking into the Toano, Virginia-based company back in 2013, he says he found online complaints about its Chinese-made flooring. So he decided to buy products from Lumber Liquidators and pay to have them analyzed. The results led him to publish a post on investing website Seeking Alpha on June 20, 2013, that advocated shorting the stock because the tests showed levels of formaldehyde above California requirements. The stock fell almost 5 percent that day.
“This report shows that Lumber Liquidators lacks a proper product quality control system, and its products may be hazardous to the unsuspecting consumers,” Zhou wrote in the post.
Profitable Short
Since Zhou began posting on Seeking Alpha, he’s also raised questions about other companies. The Los Angeles resident only manages his own money and doesn’t work for a fund, he said. Zhou made a profit shorting Lumber Liquidators and increased his bet when the company warned on Feb. 25 that the unfavorable story by “60 Minutes” was coming.
Denny Larson, executive director for environmental advocate Global Community Monitor, appeared in the “60 Minutes” piece. His group brought a complaint against Lumber Liquidators in 2014 for violating California regulations. It first learned about alleged formaldehyde issues at Lumber Liquidators from Zhou’s story, and the suit cites his reporting.
Zhou also was contacted by Tilson, who says he discovered Lumber Liquidators as a short opportunity in September. Tilson then found Zhou’s story and bet against the stock in October.
In November, Tilson announced his position at an investment conference. While his presentation concentrated on the company being investigated by the U.S. government for sourcing lumber from protected habitats, it also referenced Zhou’s story on the formaldehyde issue.
Government Case
Lumber Liquidators gave an update on the case last week, when it said that the Department of Justice may file criminal charges stemming from an inquiry that began in 2013. The company expects to be charged with a misdemeanor or felony in connection with the case, Daniel Terrell, the chief financial officer, said on a conference call.
Early last year, Tilson shifted his focus to formaldehyde after gathering more information. He did his own testing on flooring from Lumber Liquidators and it showed elevated levels of the chemical, Tilson said. After that, he pitched the story to “60 Minutes” and he was part of Sunday’s broadcast.
Zhou said he has made money from his short bet, though he declined to say how much.
“I made a profit, but it’s more than that,” Zhou said. “These are real people, real lives.”
--With assistance from Karen Gullo in federal court in San Francisco and Joshua Fineman and Arie Shapira in New York.
To contact the reporter on this story: Matt Townsend in New York at mtownsend9@bloomberg.net To contact the editors responsible for this story: Nick Turner at nturner7@bloomberg.net Kevin Orland
ANGIOSARCOMA - Don't know much about it, but been studying it for the past three weeks. My Father was diagnosed with it on 2/5/2015. He started Chemo and Radiation yesterday. What I have learned is NOT GOOD. Based on what I now understand, he has months left - AND I AM PISSED OFF. I have been watching this stock for about three years now, and believe in the science, and I do believe in the sabotage theory. I find myself VERY VERY behind in reading posts, and I read them ALL. But, I just noticed a mention of confirmed sabotage? Is this based on documents in PACER.
SOMEONE PLEASE EXPLAIN . . .
I have such anger and frustration built up over - I just might file my own law suit - I know several lawyers! I feel BAVI will save lives, an quite possibly my Dad's if not for the delay to market!
-e
I also find this interesting . . . (investor conference call at 10:00 AM EST on Thursday, February 5th).
I can't remember if they always do the conference call early in the day like that.
Any one know if this is the norm for them?